Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Rituximab 130Cyclophosphamide 113Peripheral Blood Stem Cell Transplantation 59fludarabine phosphate 55Etoposide 47Mycophenolic Acid 44Radiotherapy 41Filgrastim 41Tacrolimus 40Whole-Body Irradiation 36Busulfan 34Melphalan 33Cyclosporine 30Cytarabine 29Methotrexate 28sargramostim 27Vincristine 27Antilymphocyte Serum 27Prednisone 26Lenalidomide 23obinutuzumab 22Doxorubicin 22Carmustine 21Bortezomib 20Methylprednisolone 19fludarabine 17Dexamethasone 17Bendamustine Hydrochloride 17ibritumomab tiuxetan 15Cord Blood Stem Cell Transplantation 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, Follicular × pidilizumab × Clear all
NCT00904722 2016-06-03

Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
32 enrolled 4 charts
Lymphoid

Lymphoma, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡